Noble Financial Predicts Ocugen’s Q2 Earnings (NASDAQ:OCGN)

Ocugen, Inc. (NASDAQ:OCGN) – Stock analysts at Noble Financial upped their Q2 2025 EPS estimates for shares of Ocugen in a research note issued to investors on Monday, May 12th. Noble Financial analyst R. Leboyer now forecasts that the company will post earnings per share of ($0.06) for the quarter, up from their prior forecast of ($0.08). The consensus estimate for Ocugen’s current full-year earnings is ($0.20) per share. Noble Financial also issued estimates for Ocugen’s Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.06) EPS and FY2025 earnings at ($0.24) EPS.

OCGN has been the topic of a number of other reports. HC Wainwright reduced their target price on shares of Ocugen from $8.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday. Chardan Capital reissued a “buy” rating and set a $7.00 target price on shares of Ocugen in a research report on Monday.

Ocugen Trading Down 1.1%

OCGN opened at $0.69 on Wednesday. The firm has a market cap of $202.84 million, a P/E ratio of -3.86 and a beta of 4.21. Ocugen has a 12 month low of $0.52 and a 12 month high of $2.06. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. The stock has a 50-day moving average of $0.67 and a 200 day moving average of $0.76.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01. Ocugen had a negative net margin of 532.51% and a negative return on equity of 154.75%. The business had revenue of $1.48 million for the quarter.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers boosted its holdings in Ocugen by 12.9% in the fourth quarter. Rhumbline Advisers now owns 324,475 shares of the company’s stock valued at $261,000 after purchasing an additional 37,034 shares during the period. Geode Capital Management LLC increased its position in shares of Ocugen by 4.9% in the 4th quarter. Geode Capital Management LLC now owns 6,588,407 shares of the company’s stock valued at $5,305,000 after purchasing an additional 309,853 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Ocugen by 12.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 860,244 shares of the company’s stock valued at $692,000 after purchasing an additional 93,288 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Ocugen by 72.7% in the 4th quarter. SG Americas Securities LLC now owns 152,176 shares of the company’s stock valued at $123,000 after purchasing an additional 64,080 shares during the last quarter. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Ocugen in the 4th quarter valued at approximately $40,000. Institutional investors and hedge funds own 10.27% of the company’s stock.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.